VC
COGT icon

Vivo Capital’s Cogent Biosciences COGT Stock Holding History

Vivo Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-422,300
Closed -$16.3M – 49
2026
Q1 		$16.3M Sell
422,300
-1,976,693
-82% -$73M 1.35% 26
2025
Q4 		$85.2M Sell
2,398,993
-390,144
-14% -$11M 5.51% 4
2025
Q3 		$40.1M Buy
2,789,137
+1,666,666
+148% +$19.7M 3.22% 7
2025
Q2 		$8.06M Hold
1,122,471
– – 0.82% 27
2025
Q1 		$6.72M Hold
1,122,471
– – 0.89% 26
2024
Q4 		$8.76M Hold
1,122,471
– – 0.98% 24
2024
Q3 		$12.1M Sell
1,122,471
-1,122,470
-50% -$10.9M 1% 20
2024
Q2 		$18.9M Hold
2,244,941
– – 1.75% 14
2024
Q1 		$15.1M Hold
2,244,941
– – 1.19% 19
2023
Q4 		$13.2M Hold
2,244,941
– – 1.08% 18
2023
Q3 		$21.9M Hold
2,244,941
– – 2.4% 13
2023
Q2 		$26.6M Buy
2,244,941
+250,000
+13% +$2.87M 1.83% 12
2023
Q1 		$21.5M Hold
1,994,941
– – 1.49% 12
2022
Q4 		$23.1M Buy
1,994,941
+111,000
+6% +$1.38M 2.66% 13
2022
Q3 		$28.1M Sell
1,883,941
-37,000
-2% -$507K 3.1% 11
2022
Q2 		$17.3M Hold
1,920,941
– – 1.74% 12
2022
Q1 		$14.4M Hold
1,920,941
– – 0.99% 23
2021
Q4 		$16.5M Buy
1,920,941
+500,000
+35% +$4.35M 0.99% 25
2021
Q3 		$11.9M Buy
+1,420,941
New +$10.9M 0.54% 33

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vivo Capital's COGT Position: Q2 2026 in Review

Vivo Capital sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 422,300 shares — an estimated $16.3M sold.

Vivo Capital first reported a position in COGT in Q3 2021 and held it in 19 quarters. The position peaked at $85.2M in Q4 2025. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Vivo Capital reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Vivo Capital sold 422,300 Cogent Biosciences shares in Q2 2026, an estimated $16.3M.
  • Vivo Capital first reported a position in Cogent Biosciences in Q3 2021 and held it in 19 quarters.
  • Vivo Capital's Cogent Biosciences position peaked at $85.2M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.